EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Molecular Crosstalk Between RUNX2 and HIF-1α in Osteosarcoma: Implications for Angiogenesis, Metastasis, and Therapy Resistance

Anuja Gajanan Magar iD, Vivek Kumar Morya iD, Kyu-Cheol Noh

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26157642 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Anuja Gajanan Magar und 2 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Hallym University, Chuncheon-si 24252, Republic of Korea. Hauptthemen laut MEDLINE: Osteosarcoma, Hypoxia-Inducible Factor 1, alpha Subunit, Core Binding Factor Alpha 1 Subunit, Neovascularization, Pathologic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hallym University Medical Center, Hallym University Medical Center Research Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Runt-related transcription factor-2 (RUNX2) is an integral player in osteogenesis and is highly expressed in osteosarcoma. Emerging evidence suggests that aberrant RUNX2 expression is a key factor in osteosarcoma oncogenesis. Patients with advanced stages of osteosarcoma overexpressing RUNX2 are more likely to have high tumour grades, metastasis, and lower overall or progression-free survival rates. Thus, RUNX2 is considered a potential candidate for targeted therapy of osteosarcoma. Hypoxia-inducible factor-1α (HIF-1α) is a key transcription factor involved in the regulation of cellular reprogramming in response to hypoxia. Overexpression of HIF-1α decreases overall survival, disease-free survival, and chemotherapy response and promotes tumour stage and metastasis. Hence, our review focused on highlighting the intricate network between RUNX2 and HIF-1α, which support each other or may work synergistically to develop resistance to therapy and osteosarcoma progression. An in-depth understanding of these two important tumour progression markers is required. Therefore, this review focuses on the role of RUNX2 and HIF-1α in the alteration of the tumour microenvironment, which further promotes angiogenesis, metastasis, and resistance to therapy in osteosarcoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OsteosarcomaHypoxia-Inducible Factor 1, alpha SubunitCore Binding Factor Alpha 1 SubunitNeovascularization, PathologicDrug Resistance, NeoplasmBone NeoplasmsHumansTumor MicroenvironmentAnimalsNeoplasm MetastasisGene Expression Regulation, NeoplasticAngiogenesis

Stichwörter der Autor:innen

HIF-1αRUNX2angiogenesismetastasisosteosarcomatherapy resistance

Substanzen

Hypoxia-Inducible Factor 1, alpha SubunitCore Binding Factor Alpha 1 SubunitRUNX2 protein, humanHIF1A protein, human

Autor:innen und Institutionen

  • School of Medicine, Hallym University, Chuncheon-si 24252, Republic of Korea.
  • Hallym University Sacred Heart Hospital, Anyang-si 14068, Republic of Korea.

ORCID-Profile: Anuja Gajanan Magar, Vivek Kumar Morya

Förderung

  • Hallym University Medical Center
  • Hallym University Medical Center Research Fund

Zitieren

APA

Magar, A. G., Morya, V. K., & Noh, K. C. (2025). Molecular Crosstalk Between RUNX2 and HIF-1α in Osteosarcoma: Implications for Angiogenesis, Metastasis, and Therapy Resistance. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26157642

Vancouver

Magar AG, Morya VK, Noh KC. Molecular Crosstalk Between RUNX2 and HIF-1α in Osteosarcoma: Implications for Angiogenesis, Metastasis, and Therapy Resistance. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26157642

BibTeX
@article{Magar2025,
  author = {Magar, Anuja Gajanan and Morya, Vivek Kumar and Noh, Kyu-Cheol},
  title = {Molecular Crosstalk Between RUNX2 and HIF-1α in Osteosarcoma: Implications for Angiogenesis, Metastasis, and Therapy Resistance},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26157642}
}
Kostenlos starten →